Aerie Pharma to use DSM polymers to develop eye drug delivery tech

iStock/kwasny221

Aerie Pharmaceuticals Inc will use a DSM polymer technology to develop an implant to deliver AR-13154, its wet AMD drug candidate.

Under the collaboration the California, US-based drug firm will use polyesteramide polymer (PEA) technology – the degradation of which can be controlled – to make an injectable fibre that releases the active pharmaceutical ingredient (API) over an extended period.

The initial focus of the research will be AR-13154, a small molecule candidate that inhibits enzymes involved in the development of lesions characteristic of wet age-related macular degeneration (AMD).

However, the accord – financial terms of which were not disclosed – permits Aerie to apply the technology to other candidate compounds in its pipeline.

CEO Vicente Anido said: “Unlocking the potential of AR-13154 and related Aerie-owned compounds for the treatment of retinal diseases is the identification of the appropriate technology to achieve longer-term sustained delivery of our small molecules to the back of the eye.”

Related News

Aerie to build manufacturing facility in Ireland

Aerie to build manufacturing facility in Ireland

News from Onconova, Halozyme and Rib-X Pharmaceuticals – People on the move

News from Onconova, Halozyme and Rib-X Pharmaceuticals – People on the move

New EU guidance on GDP for biopharmaceuticals comes into force

Sonoco Launches New 'Shippers' to Ensure Cold Chain

Related Products

See more related products